EMA reviews CV risk in NSAIDs and cancer risk in Protelos; concludes ARB review
21 October 2011
Francesca Bruce
Please Login to read the full article.
21 October 2011
Francesca Bruce
Please Login to read the full article.
RELATED CONTENT
NEWS
- Servier bone drug Protelos avoids French suspension but goes to EMA for safety review
- Servier hit by bone drug safety issues as Mediator continues to make waves
- GTx shares dive as clot threat brings FDA clinical hold for prostate cancer product
- Xarelto gains US FDA reviewer's support in ACS ahead of cardiac panel
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
